Bystander effect of IL-12 and P53 gene therapy in the head and neck
Bystander effect of IL-12 and P53 gene therapy in the head and neck
批准号:
13671792
负责人:
TSUKUDA Mamoru
金额:
$2.62万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The research was mainly focused on IL-12 gene therapy. Human KB cells transfected hIL-12 gene(KB/IL-12) produced IL-12 in the culture supernatant. KB/IL-12 cells showed a strong anti-tumor potential through elevated immunity. On the other hand direct administration of mIL-12 gene to inoculated tumors with NR-S1 (murine oral carcinoma) resulted in IFN-γ production and anti-tumor effects. The mRNA expression of VEGF in NR-S1 cells transfected with mIL-12 gene decreased significantly, compared to non-treated NR-S1 cells.Furthermore, combined treatment with IL-12 gene therapy and chemotherapy, e. g. CDDP or UFT, showed a compete response in the murine model. The mechanisms of anti-tumor effects were considered to be induction of apoptosis, ant angiogenesis, immunological enhancement with the accumulation of CD8+ and CD56+ in the tumor site and synergistic effects of both treatments, especially immunological augmentation of IL-12 gene therapy on the deteriorated immunity by chemotherapy.In ELISPOT analysis, IFN-γ positive spleen cells increased in the mice group receiving IL-12 gene therapy, compared to those in the control one. This result showed Th_1 predominant condition caused by IL-12 gene therapy.In conclusion, IL-12 gene therapy not only augments local and systemic immunity and induce apoptotic change of tumor cells, but also suppresses angiogenesis of tumors, resulting in anti-tumor effects through comprehensive mechanisms.
期刊论文(12)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
M Tsukuda: "Induction of sparc by VEGF in human vascular endotherial cells"Biochem Biopyhs Rca Commun. 287(2). 422-426 (2001)
M Tsukuda:“人血管内皮细胞中 VEGF 诱导 sparc”Biochem Biopyhs Rca Commun。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
佃 守: "21世紀耳鼻咽喉科 領域の臨床18免疫アレルギー疾患 Biological response modifier(BRM)とサイトカインによる治療"中山書店. 11 (2001)
Mamoru Tsukuda:“21世纪耳鼻喉科领域的临床18种免疫过敏性疾病。生物反应调节剂(BRM)和细胞因子的治疗”Nakayama Shoten 11(2001)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
M Tsakuda: "Reduced expression of p16 and p27 proteifls in nasopharyngeal carcinoma"Cancer Deteciori and Prevention. 25(5). 414-419 (2001)
M Tsakuda:“鼻咽癌中 p16 和 p27 蛋白的表达降低”癌症检测和预防。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
佃 守: "頭頸部癌新しい治療の展開"癌と化学療法. 28(4). 464-474 (2001)
Mamoru Tsukuda:“头颈癌新疗法的开发”《癌症与化疗》28(4) (2001)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
M Tsukuda: "The inhibitory effects of TNP470 on tumour growth of head and neck carcinoma cell producing iiiterleukin-8"J Laryngol Otol. 115(10). 802-807 (2001)
M Tsukuda:“TNP470 对产生 iiiterleukin-8 的头颈癌细胞肿瘤生长的抑制作用”J Laryngol Otol。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 12 条
Studies on effective molecular targeted therapy for head and neck cancer
-
批准号:18591877
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.53万
-
财政年份:2006
-
负责人:TSUKUDA Mamoru
-
依托单位:
Basic studies of IL-2 gene therapy for head and neck cancer
-
批准号:10671605
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:1998
-
负责人:TSUKUDA Mamoru
-
依托单位:
Basic studies on chemoprevention for head and neck cancer
-
批准号:08671977
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.22万
-
财政年份:1996
-
负责人:TSUKUDA Mamoru
-
依托单位:
Studies on immuno-chemotherapy regulating metastatic factors in head and neck carcinomas
-
批准号:05671437
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.41万
-
财政年份:1993
-
负责人:TSUKUDA Mamoru
-
依托单位:
海外基金